IN8bio, Inc.

The momentum for this stock is not very good. IN8bio, Inc. has good growth characteristics. IN8bio, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in IN8bio, Inc..

News

IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy

FierceBiotech.com - Biotech IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy\ndincorvaia\nWed, 09/04/2024 - 18:12...\n more…

IN8bio to reduce workforce by 49%

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

IN8bio suspends patient enrollment in INB-400, to focus on INB-100

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Globe Newswire Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support...\n more…

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...\n more…

Head to Head Comparison: IN8bio (NASDAQ:INAB) versus BioNTech (NASDAQ:BNTX)

Ticker Report BioNTech (NASDAQ:BNTX - Get Free Report) and IN8bio (NASDAQ:INAB - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the...\n more…